Digestive System Neoplasms: Clinical Trials

260 trials for Digestive System Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

64 unknown, 63 completed, 41 recruiting, 30 terminated. 260 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 1260Unknown 64, Completed 63, Recruiting 41, Terminated 30, Not yet recruiting 23, Withdrawn 17, Active not recruiting 14, Enrolling by invitation 5, Suspended 3

Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms

Trials (filtered) newest first · largest first

All 260 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NK521 in the Treatment of Advanced Solid Tumors
NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer
Early Phase 1Not yet recruitingBase Therapeutics (Shanghai) Co., Ltd.182027-01-012026-09-30
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
ICI Therapy - Gastrointestinal Neoplasms, Genitourinary Cancer
Early Phase 1Not yet recruitingIndiana University802027-01-012026-11-18
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
GLP1-RA (semaglutide) - Pancreatic Cancer, Colorectal Cancer
Early Phase 1RecruitingUniversity of Arizona302026-10-072026-11-16
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
CBG131 CAR-T Cell Infusion - Advanced Gastric and Pancreatic Cancer
Early Phase 1Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University182026-09-302026-02-06
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
ateganosine, Cadonilimab - Resectable Hepatocellular Carcinoma
Early Phase 1RecruitingUniversity of Texas Southwestern Medical Center602026-09-012026-09-03
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
[64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma
Early Phase 1Not yet recruitingLumina Pharmaceuticals Inc402026-09-012026-08-28
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
Autologous Cytokine-Induced Killer (CIK) Cells - Hepatocellular Carcinoma (HCC)
Early Phase 1Not yet recruitingRoyan Institute62026-07-012026-07-16
Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors
[⁶⁸Ga]Ga-HT547 and [¹⁷⁷Lu]Lu-HT547 - Breast Cancer, Head and Neck Cancer (H&N)
Early Phase 1Not yet recruitingHua Pang202026-06-012026-06-10
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
[68Ga]/ [131I]-IR199 - Gastric Cancer, Pancreatic Cancer
Early Phase 1RecruitingHuashan Hospital102026-06-012026-07-16
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
ES502 Injection - Pancreatic Cancer
Early Phase 1RecruitingRuijin Hospital242026-05-182026-06-16
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
Stereotactic Body Radiation Therapy (SBRT), Botensilimab, Balstilimab - Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Early Phase 1RecruitingMassachusetts General Hospital152026-05-122026-05-13
A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33
GPA33-CC;177Lu-SmartD2 - Colorectal Cancer
Early Phase 1Not yet recruitingSmartNuclide Biopharma202026-05-012026-05-15
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer
Early Phase 1RecruitingM.D. Anderson Cancer Center1002026-04-222026-10-14
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
[68Ga]Ga-ABY-025 - Locally Advanced Cancer, Metastatic Cancer
Early Phase 1RecruitingVanderbilt-Ingram Cancer Center302026-04-162026-05-08
Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
Peginterferon alfa-2b, TDF, TAF - Hepatocellular Carcinoma, HEPATITIS B CHRONIC
Early Phase 1Not yet recruitingNingbo No.2 Hospital1562026-03-312026-04-28
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
Metabolically Armed GPC3 CAR-T cells - Hepatocellular Carcinoma (HCC)
Early Phase 1Not yet recruitingZhejiang University272026-03-302026-04-21
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
KT032(anti-MSLN chimeric antigen receptor autologous T cell injection) - Ovarian Cancer, Mesothelioma
Early Phase 1Not yet recruitingWeijia Fang, MD242026-03-152026-02-19
B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.
blood plasma sample, blood sampling - Breast Cancer, Pancreatic Cancer
Early Phase 1RecruitingPoitiers University Hospital2202026-02-032026-02-05
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab - Colorectal Cancer Metastatic, Colorectal Cancer Stage III
Early Phase 1RecruitingBiogenea Pharmaceuticals Ltd.122026-02-022026-01-09
Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
68Ga-XH06 - Malignant Neoplasm of Liver
Early Phase 1Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1502026-01-302026-01-20

Showing 20 of 260. Sign in to see all of them.

Narrower conditions

Pancreatic Neoplasms (81)  ·  Colorectal Neoplasms (56)  ·  Carcinoma, Hepatocellular (53)  ·  Stomach Neoplasms (36)  ·  Colonic Neoplasms (26)  ·  Breast Neoplasms (25)  ·  Lung Neoplasms (16)  ·  Ovarian Neoplasms (15)  ·  Liver Neoplasms (13)  ·  Rectal Neoplasms (12)  ·  Esophageal Neoplasms (11)  ·  Gastrointestinal Neoplasms (11)  ·  Neoplasms (11)  ·  Sarcoma (11)  ·  Carcinoma, Non-Small-Cell Lung (8)

Broader conditions

Digestive System Diseases (260)  ·  Neoplasms by Site (258)  ·  Neoplasms (249)  ·  Gastrointestinal Diseases (134)  ·  Gastrointestinal Neoplasms (123)  ·  Endocrine Gland Neoplasms (94)  ·  Endocrine System Diseases (94)  ·  Intestinal Diseases (88)  ·  Intestinal Neoplasms (88)  ·  Neoplasms by Histologic Type (88)  ·  Pancreatic Diseases (86)  ·  Colonic Diseases (83)  ·  Neoplasms, Glandular and Epithelial (80)  ·  Carcinoma (66)

Interventions

Magnetic Resonance Spectroscopy (11)  ·  Fluorouracil (8)  ·  Oxaliplatin (8)  ·  Biopsy (6)  ·  Gemcitabine (6)  ·  Irinotecan (6)  ·  Leucovorin (6)  ·  Bevacizumab (5)  ·  Nivolumab (5)  ·  Radiosurgery (5)  ·  Capecitabine (4)  ·  Oncolytic Virotherapy (4)  ·  Radiation (4)  ·  Specimen Handling (4)  ·  lenvatinib (4)

Sponsors

Peking Union Medical College Hospital (6)  ·  Beijing Ditan Hospital (5)  ·  Massachusetts General Hospital (5)  ·  Mayo Clinic (5)  ·  OHSU Knight Cancer Institute (5)  ·  Ruijin Hospital (5)  ·  Shanghai Yunying Medical Technology (5)  ·  BioSyngen Pte Ltd (4)  ·  Case Comprehensive Cancer Center (4)  ·  H. Lee Moffitt Cancer Center and Research Institute (4)  ·  M.D. Anderson Cancer Center (4)  ·  National Cancer Institute (NCI) (4)  ·  Shanghai Changzheng Hospital (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  Base Therapeutics (Shanghai) Co., Ltd. (3)

Countries

United States (107)  ·  China (92)  ·  France (4)  ·  Netherlands (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  Egypt (2)  ·  Spain (2)  ·  Belgium (1)  ·  Greece (1)  ·  India (1)  ·  Iran (1)  ·  Iraq (1)  ·  Ireland (1)

Top investigators

Alexander Guimaraes (2)  ·  Baiyong Shen (2)  ·  Charles D Lopez (2)  ·  Mingyong Han, PhD (2)  ·  Mingyu Sun, doctor (2)  ·  Scott Irwin, MD, PhD (2)  ·  Wei-Fen Xie, M.D. (2)  ·  Yuqing Li, PhD (2)  ·  Zhaohui Zhu (2)  ·  Aaron J Scott, MD (1)  ·  Aaron Weitzman, MD (1)  ·  Adam H Buchanan, MS, MPH, CGC (1)  ·  Ahmed E Mohamed, Master (1)  ·  Ajay Jain, MD (1)  ·  Ajit H Goenka, MD (1)

Results publications

PMID 17197840, PMID 17701250, PMID 19095497, PMID 20518581, PMID 22321518, PMID 23340005, PMID 24493717, PMID 24614108, PMID 24696183, PMID 25027973, PMID 25209657, PMID 25691612, PMID 26674592, PMID 27275632, PMID 27918777, PMID 29471013, PMID 30207593, PMID 30220234, PMID 30959462, PMID 31063184, PMID 31070690, PMID 31579027, PMID 31592772, PMID 31858837, PMID 32414353, PMID 32497895, PMID 33365268, PMID 33538338, PMID 34376577, PMID 34729628, PMID 35303929, PMID 35660135, PMID 35708168, PMID 36512649, PMID 36748942, PMID 36990609, PMID 37344887, PMID 38325328, PMID 38926162, PMID 38970713, PMID 39448271, PMID 39499011, PMID 40115982, PMID 40135850, PMID 40914168, PMID 41101974, PMID 41193187, PMID 41556358, PMID 41688850, PMID 41878443

NIH funding

P30CA033572 (2), P30CA068485 (2), K01DK120742 (1), P30CA006973 (1), P30CA014089 (1), P30CA043703 (1), P30CA046934 (1), P30CA060553 (1), P30CA072720 (1), P30CA093373 (1), P30CA124435 (1), P30CA138292 (1), P50CA127003 (1), R01CA154982 (1), R01CA243014 (1)